Short answer
NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
NovoCure Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed results and management commentary
- Results update provides investors with current operating and financial performance information
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $193.4M, up 16% YoY, driven by 19% global active-patient growth to 5,260
- Gross margin 77% vs 73%, while adjusted EBITDA reached $15.7M and net loss narrowed to $10.4M
- 2026 guidance raised: revenue $736M-$743M and adjusted EBITDA $24M-$34M
- Optune Pax approved in Japan for locally advanced pancreatic cancer, expanding commercial opportunity beyond U.S. and Germany
- Cash, equivalents and short-term investments $463.5M, with $25M current credit-facility maturity and $171.3M long-term debt
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NovoCure Ltd 8-K filings
Get the next NVCR 8-K as it lands
Follow NVCR for push alerts, or ask the research agent what this filing means.